SCHEMBL5772203

SCHEMBL5772203

c1ccc(CN2CCc3c(CN4CCCC4)ncnc3C2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIMK1 P53667 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
ALDH1A1 P00352 3/20 0.43
HPGD P15428 3/20 0.43
KDM4E B2RXH2 2/20 0.43
HIF1A Q16665 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
SIGMAR1 Q99720 1/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SLC6A5 Q9Y345 1/20 0.41
PNMT P11086 1/20 0.41
C5AR1 P21730 1/20 0.41
MKNK1 Q9BUB5 2/20 0.41
CLPP Q16740 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5777690 0.99 HRH3 (0.47) LIMK1HRH3KMT2AMEN1ALDH1A1
SCHEMBL5778903 0.84 C5AR1 (0.43) LIMK1KMT2AMEN1GAAC5AR1
SCHEMBL4079977 0.83 LIMK1 (0.49) LIMK1KMT2AMEN1ALDH1A1HPGD
Hydrochloric Acid SCHEMBL4982981 0.82 LIMK1 (0.48) LIMK1KMT2AMEN1ALDH1A1HPGD
SCHEMBL1549990 0.81 KMT2A (0.51) LIMK1KMT2AMEN1ALDH1A1HPGD
SCHEMBL14111444 0.80 LIMK1 (0.49) LIMK1KMT2AMEN1ALDH1A1HPGD
SCHEMBL4982960 0.80 LIMK1 (0.61) LIMK1KMT2AMEN1ALDH1A1HPGD
SCHEMBL4975207 0.80 ALDH1A1 (0.49) HRH3ALDH1A1HPGDKDM4EHIF1A
SCHEMBL5777580 0.80 FAAH (0.51) HRH3KMT2AMEN1ALDH1A1HPGD
SCHEMBL12386805 0.79 P2RX7 (0.50) LIMK1KMT2AMEN1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1483257-B1 QUINAZOLINE COMPOUNDS USEFUL IN THERAPY PFIZER LTD (GB) 2006-09-13 EP disclosed
US-6936619-B2 Cardiovascular disorders; antilipemic agents; sexual disorders PFIZER, INC. (US) 2005-08-30 US disclosed
US-20040029859-A1 Compounds useful in therapy PFIZER INC. 2004-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029859-A1 Compounds useful in therapy ADRA1D, HSD3B1, PTGER1 LIMK1 4646/4885HRH3 170/4885KMT2A 3583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.